Eating This Reduces Visceral Fat

Why It Matters

Reducing visceral fat with a simple, evidence‑backed dietary component like RS2 could lower chronic disease risk and improve metabolic health, offering a scalable, low‑cost intervention for consumers and clinicians alike.

Key Takeaways

• Resistant starches (RS2) significantly cut visceral fat in trials.
• Studies used 40 g daily, showing measurable health improvements.
• Visceral fat links to insulin resistance, mortality, and inflammation.
• RS2 benefits extend beyond fat loss to broader metabolic health.
• Incorporating RS2 may be a simple, evidence‑based dietary tweak.

Summary

The video highlights resistant starches, specifically RS2, as a potent dietary tool for reducing visceral fat. Citing large‑scale Nature Metabolism and Cell Metabolism trials, the presenter notes that a daily dose of 40 g of RS2 produced statistically significant visceral fat loss compared with placebo.

Visceral fat, unlike subcutaneous fat, surrounds internal organs and drives insulin resistance, chronic inflammation, and higher mortality risk. The studies referenced demonstrated not only a reduction in fat volume but also improvements in metabolic markers, underscoring the clinical relevance of the findings.

The speaker emphasizes personal adoption, noting that despite a long‑standing supplement regimen, RS2 was the first addition prompted by the evidence. He distinguishes visceral from subcutaneous fat and stresses that the health stakes of the former are far greater, making the observed reductions especially noteworthy.

If these results translate to broader populations, RS2 could become a low‑cost, non‑pharmacologic strategy for combating metabolic disease. The upcoming content promises deeper dives into the broader benefits of resistant starches, suggesting a growing interest in functional foods for preventive health.

Original Description

Resistant starch can cut visceral fat and liver fat — even when people don’t change the rest of their diet. 🧬

Several randomized controlled trials showed that adding resistant starch significantly reduced visceral fat and improved liver health.

In one trial, people taking resistant starch had over far greater visceral fat elimination than placebo, with nearly 20% more visceral fat lost over four months.

Resistant starch also reduced intrahepatic fat (IHTG) or the fat inside liver cells. In one study, the resistant starch group eliminated about six times more liver fat than the placebo group.

These improvements were also accompanied by better inflammation and liver damage markers.

Resistant starch is not absorbed into the bloodstream. Instead, it reaches the large intestine, where it is fermented by gut microbes.

Researchers found that microbiome changes from resistant starch alone could improve liver health when transferred into from humans to mice.

The file also notes that when resistant starch is missing, a particular bacterium becomes more abundant. In mice, exposure to that bacterium was linked to worse liver fat outcomes.

Not everyone responds the same way. Some people had large drops in liver fat, while others had only small improvements.

Researchers described these groups as high responders and low responders, with the microbiome being the leading explanation for the difference.

Common sources include high-amylose maize starch, green banana powder, and potato starch.

Across the studies, the consistent dose was around 40 grams per day. Ramp up slowly, starting around 5 grams per day, then increasing gradually to reduce gas, bloating, and other gastrointestinal discomfort.

Main Points Summary:

Resistant starch consistently reduced visceral fat and liver fat across multiple trials; it worked through the gut microbiome rather than direct absorption; around 40 grams per day was the best-supported dose, with gradual increase recommended. 📌

References:

Ni — Cell Metabolism — 2023 — 10.1016/j.cmet.2023.08.002

Long — Cell Metabolism — 2025 — 10.1016/j.cmet.2025.10.017

Li — Nature Metabolism — 2024 — 10.1038/s42255-024-00988-y

Zhang — Scientific Reports — 2019 — 10.1038/s41598-018-38216-9

Peterson — American Journal of Clinical Nutrition — 2018 — 10.1093/ajcn/nqy121

Johnston — Diabetic Medicine — 2010 — 10.1111/j.1464-5491.2010.02923.x